Guggenheim Capital LLC Sarepta Therapeutics, Inc. Transaction History

Guggenheim Capital LLC

$14 Billion
Q3 2024

A detailed history of Guggenheim Capital LLC transactions in Sarepta Therapeutics, Inc. stock. As of the latest transaction made, Guggenheim Capital LLC holds 32,647 shares of SRPT stock, worth $4.26 Million. This represents 0.03% of its overall portfolio holdings.

Number of Shares

32,647

Previous 30,874 5.74%

Holding current value

$4.26 Million

Previous $4.88 Million 16.42%

% of portfolio

0.03%

Previous 0.04%

29 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 13, 2024	BUY	$124.33 - $156.75 $220,437 - $277,917	1,773 Added 5.74%	32,647 $4.08 Million
Q2 2024 Aug 14, 2024	BUY	$113.33 - $163.85 $514,404 - $743,715	4,539 Added 17.24%	30,874 $4.88 Million
Q1 2024 May 14, 2024	BUY	$93.7 - $141.53 $236,686 - $357,504	2,526 Added 10.61%	26,335 $3.41 Million
Q4 2023 Feb 14, 2024	BUY	$67.31 - $124.76 $19,452 - $36,055	289 Added 1.23%	23,809 $2.3 Million
Q3 2023 Nov 14, 2023	SELL	$102.5 - $123.59 $42,230 - $50,919	-412 Reduced 1.72%	23,520 $2.85 Million
Q2 2023 Aug 11, 2023	BUY	$106.4 - $157.19 $11,916 - $17,605	112 Added 0.47%	23,932 $2.74 Million
Q1 2023 May 10, 2023	SELL	$117.53 - $155.99 $787,686 - $1.05 Million	-6,702 Reduced 21.96%	23,820 $3.28 Million
Q4 2022 Feb 14, 2023	SELL	$100.86 - $132.13 $148,970 - $195,156	-1,477 Reduced 4.62%	30,522 $3.96 Million
Q3 2022 Nov 14, 2022	SELL	$75.71 - $119.24 $720,229 - $1.13 Million	-9,513 Reduced 22.92%	31,999 $3.54 Million
Q2 2022 Aug 15, 2022	BUY	$62.69 - $88.44 $1,379 - $1,945	22 Added 0.05%	41,512 $3.11 Million
Q1 2022 May 16, 2022	SELL	$63.15 - $90.42 $24,502 - $35,082	-388 Reduced 0.93%	41,490 $3.24 Million
Q4 2021 Feb 14, 2022	BUY	$77.28 - $99.42 $297,914 - $383,264	3,855 Added 10.14%	41,878 $3.77 Million
Q3 2021 Nov 15, 2021	SELL	$65.97 - $92.48 $48,356 - $67,787	-733 Reduced 1.89%	38,023 $3.52 Million
Q2 2021 Aug 13, 2021	SELL	$69.38 - $86.75 $200,508 - $250,707	-2,890 Reduced 6.94%	38,756 $3.01 Million
Q1 2021 May 13, 2021	BUY	$72.25 - $168.95 $802,264 - $1.88 Million	11,104 Added 36.36%	41,646 $3.1 Million
Q4 2020 Feb 16, 2021	SELL	$125.56 - $178.74 $421,756 - $600,387	-3,359 Reduced 9.91%	30,542 $5.21 Million
Q3 2020 Nov 13, 2020	SELL	$127.12 - $172.34 $660,769 - $895,823	-5,198 Reduced 13.29%	33,901 $4.76 Million
Q2 2020 Aug 14, 2020	BUY	$93.0 - $171.7 $466,860 - $861,934	5,020 Added 14.73%	39,099 $6.27 Million
Q1 2020 Jun 02, 2020	SELL	$82.38 - $131.64 $577,813 - $923,322	-7,014 Reduced 17.07%	34,079 $3.33 Million
Q4 2019 Feb 14, 2020	SELL	$76.53 - $135.58 $147,626 - $261,533	-1,929 Reduced 4.48%	41,093 $5.3 Million
Q3 2019 Nov 14, 2019	BUY	$72.81 - $156.91 $208,018 - $448,291	2,857 Added 7.11%	43,022 $3.24 Million
Q2 2019 Aug 14, 2019	SELL	$112.21 - $151.95 $718,144 - $972,479	-6,400 Reduced 13.74%	40,165 $6.1 Million
Q1 2019 May 15, 2019	SELL	$106.67 - $151.68 $177,605 - $252,547	-1,665 Reduced 3.45%	46,565 $5.55 Million
Q4 2018 Feb 14, 2019	BUY	$97.32 - $148.76 $568,154 - $868,460	5,838 Added 13.77%	48,230 $5.26 Million
Q3 2018 Nov 14, 2018	SELL	$115.31 - $161.51 $838,880 - $1.17 Million	-7,275 Reduced 14.65%	42,392 $6.85 Million
Q2 2018 Aug 14, 2018	SELL	$71.74 - $153.69 $525,782 - $1.13 Million	-7,329 Reduced 12.86%	49,667 $6.56 Million
Q1 2018 May 15, 2018	SELL	$54.02 - $82.27 $451,121 - $687,036	-8,351 Reduced 12.78%	56,996 $4.22 Million
Q4 2017 Feb 14, 2018	SELL	$47.64 - $56.75 $875,146 - $1.04 Million	-18,370 Reduced 21.94%	65,347 $3.64 Million
Q3 2017 Nov 14, 2017	BUY	$35.73 - $47.15 $2.99 Million - $3.95 Million	83,717	83,717 $3.8 Million

Others Institutions Holding SRPT

# of Institutions

530

Shares Held

84.5M

Call Options Held

2.06M

Put Options Held

1.52M

View Full List

About Sarepta Therapeutics, Inc.

Ticker SRPT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 87,567,904
Market Cap $11.4B
Description
Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mut...

More about SRPT

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Guggenheim Capital LLC, based on Form 13F filings with the SEC.

News

Stay updated on Guggenheim Capital LLC with notifications on news.

Account

Guggenheim Capital LLC Sarepta Therapeutics, Inc. Transaction History